Wann LS,Lee R,Santangeli P,Natale A.,Managing Atrial Fibrillation Insights Into Pathophysiology A. . .. [Last cited on 2013 Aug, 14 : .
Society HR. Heart,Diseases HR. Heart . .. [Last cited on 2013 Aug, 14 : .
Fuster V,Rydén LE,Cannom DS,Crijns HJ,Curtis AB,Ellenbogen KA .2011 .Management of patients with atrial fibrillation;. [Last cited on 2013 Aug, 14 : .
Hart RG,Pearce L A,Aguilar MI .2007 .Meta‑analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 146 : 857-67.
Strobeck JE .2012 .Stroke prevention in atrial fibrillation: Managing the risks in light of new oral anticoagulants. Cardiovasc Drugs Ther, 26 : 331-8.
Providência R,Albenque JP,Combes S,Bouzeman A,Casteigt B,Combes N .2014 .Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: A systematic review and meta‑analysis. Heart, 100 : 324-35.
Sacco RL,Kasner SE,Broderick JP,Caplan LR,Connors JJ,Culebras A .2013 .An updated definition of stroke for the 21st century: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 44 : 2064-89.
Ezekowitz MD,Reilly PA,Nehmiz G,Simmers TA,Nagarakanti R,Parcham‑Azad K .2007 .Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol, 100 : 14192-6.
Connolly SJ,Ezekowitz MD,Yusuf S,Eikelboom J,Oldgren J,Parekh A .2009 .Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 361 : 1139-51.
Ezekowitz MD,Wallentin L,Connolly SJ,Parekh A,Chernick MR,Pogue J .2010 .Dabigatran and warfarin in Vitamin K antagonist‑naive and ‑experienced cohorts with atrial fibrillation. Circulation, 122 : 2246-53.
Diener HC,Connolly SJ,Ezekowitz MD,Wallentin L,Reilly PA,Yang S .2010 .Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE‑LY trial. Lancet Neurol, 9 : 1157-63.
Hori M,Connolly SJ,Ezekowitz MD,Reilly PA,Yusuf S,Wallentin L,RE‑LY Investigators L .2011 .Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation - Suba‑nalysis in Japanese population in REL‑Y trial. Circ J, 75 : 800-5.
Pink J,Lane S,Pirmohamed M,Hughes DA .2011 .Dabigatran etexilate versus warfarin in management of nonv‑alvular atrial fibrillation in UK context: Quantitative benefith‑arm and economic analyses. BMJ, 343 : d6333.
Eikelboom JW,Wallentin L,Connolly SJ,Ezekowitz M,Healey JS,Oldgren J .2011 .Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long‑term anticoagulant therapy (RE‑LY) trial. Circulation, 123 : 2363-72.
Nagarakanti R,Ezekowitz MD,Oldgren J,Yang S,Chernick M,Aikens TH .2011 .Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion. Circulation, 123 : 131-6.
Hart RG,Diener HC,Yang S,Connolly SJ,Wallentin L,Reilly PA .2012 .Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE‑LY trial. Stroke, 43 : 1511-7.
Guo Y,Pisters R,Apostolakis S,Blann AD,Wang H,Zhao X .2013 .Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: Would the novel oral anticoagulants have an impact?. Int J Cardiol, 168 : 515-22.
Schneeweiss S,Gagne JJ,Patrick AR,Choudhry NK,Avorn J .2012 .Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes, 5 : 480-6.
Healey JS,Eikelboom J,Yang S,Themeles E,Connolly SJ,Yusuf S .2013 .Response to letters regarding article, Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the randomized evaluation of longt‑erm anticoagulation therapy (REL‑Y) randomized trial. Circulation, 127 : e506.
Eikelboom J,Connolly SJ,Hart RG,Wallentin L,Reilly P,Oldgren J .2012 .Balancing the Benefits and risks of two doses of dabigatran compared with warfarin in atrial fibrillation. Circulation, 126 : A14433.
Hori M,Connolly SJ,Zhu J,Liu LS,Lau CP,Pais P .2013 .Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and nonA‑sians with atrial fibrillation. Stroke, 44 : 18916.
Flaker G,Ezekowitz M,Yusuf S,Wallentin L,Noack H,Brueckmann M .2012 .Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: Results from the RE‑LY (Randomized Evaluation of LongT‑erm Anticoagulation Therapy) study. J Am Coll Cardiol, 59 : 854-5.
Lip GY,Rasmussen LH,Olsson SB,Jensen EC,Persson AL,Eriksson U .2009 .Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation: A randomized dose‑guiding, safety, and tolerability study of four doses of AZD0837 vs. Vitamin K antagonists. Eur Heart J, 30 : 2897-907.
Oldgren J,Ezekowitz MD,Alings M,Diener HC,Reilly PA,Yusuf S .2011 .Dabigatran versus warfarin and impact of CHAD2V‑ASC score on outcome in atrial fibrillation patients: A RE‑LY subgroup analysis. J Am Coll Cardiol, 14 : E7.
Site HG .2006 .Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): A randomised controlled trial. Lancet, 367 : 1903-12.
Mackman N. .2009 .The role of tissue factor and factor VIIa in hemostasis. Anesth Analg, 108 : 1447-52.
Steffel J,Lüscher TF,Tanner FC .2006 .Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications. Circulation, 113 : 722-31.
Hirsh J,Dalen J,Anderson DR,Poller L,Bussey H,Ansell J .2001 .Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 119 1 Suppl: : 8S-21S.